MDM2 ligase, coupled with inhibitors of the targets BCL2L1, BRD4, CDK9, PLK1 and MCL1 in stomach cancer, and MDM2 with PIK3C3 inhibitors in breast cancer seemed to be the best therapeutic construction. This evidence concerns the gene PLK1 and breast cancer.